Ketamine and Epigenetic Aging
NCT05294835 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2022-09-08
Summary
This is a prospective, clinical pilot study (n=20) to evaluate the impact of a ketamine treatment for Major Depressive Disorder (MDD) or Post Traumatic Stress Disorder (PTSD) on epigenetic aging by the TruAge epigenetic age laboratory test.
Conditions
- Depression
- Post Traumatic Stress Disorder
Interventions
- DRUG
-
ketamine infusion
Sponsors & Collaborators
-
Wild Health
collaborator UNKNOWN -
TruDiagnostic
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 64 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-04-01
- Primary Completion
- 2022-12-31
- Completion
- 2022-12-31
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Ketamine for Treatment Resistant Late-Life Depression
NCT02556606 ·Status: COMPLETED ·Phase: PHASE3
-
Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine
NCT04216888 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant Depression
NCT04239963 ·Status: COMPLETED
-
Low Dose Ketamine Infusion for the Treatment of Resistant Depression
NCT04283058 ·Status: WITHDRAWN
-
Biomarkers of Fast Acting Therapies in Major Depression
NCT02165449 ·Status: COMPLETED ·Phase: PHASE1
-
Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients
NCT02106325 ·Status: COMPLETED ·Phase: PHASE2
-
Optimization of IV Ketamine for Treatment Resistant Depression
NCT00768430 ·Status: COMPLETED ·Phase: PHASE2
-
Ketamine Treatment Plans for Chronic Conditions
NCT06038409 ·Status: RECRUITING
-
Investigation of Antidepressant Efficacy of Oral Ketamine Treatment
NCT02992496 ·Status: UNKNOWN ·Phase: PHASE2
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
NCT03065335 ·Status: RECRUITING ·Phase: PHASE1
-
The UTHealth Ketamine Project
NCT02882711 ·Status: TERMINATED ·Phase: PHASE2
-
An EEG Study of Intravenous Ketamine for Major Depression Disorder
NCT05506462 ·Status: UNKNOWN ·Phase: PHASE4
-
Clinical Trial of the Use of Ketamine in Treatment Resistant Depression
NCT02610712 ·Status: UNKNOWN ·Phase: PHASE4
-
Ketamine Anesthesia for Improvement of Depression in ECT
NCT02752724 ·Status: COMPLETED ·Phase: NA
-
Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder
NCT01667926 ·Status: COMPLETED ·Phase: NA
-
A Naturalistic Study of Ketamine for Treatment Resistant Mood Disorders
NCT04226963 ·Status: COMPLETED
-
ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)
NCT03113968 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Ketamine for Major Depressive Disorder
NCT03721900 ·Status: UNKNOWN ·Phase: PHASE1
-
Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression
NCT05045378 ·Status: COMPLETED ·Phase: PHASE4
-
Understanding and Treating Suicidal Ideation With Ketamine
NCT06891300 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Rapid Antidepressant Effects of Ketamine in Major Depression
NCT00088699 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression
NCT06559826 ·Status: RECRUITING ·Phase: PHASE2
-
Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts
NCT07139106 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Intravenous Ketamine Effects on Functional Neuroanatomy
NCT04205890 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Single Ketamine Infusion Combined With Music for Suicidal Ideation
NCT04658420 ·Status: UNKNOWN ·Phase: PHASE2